OBJECTIVES: To compare and explain current drug pricing systems in Bosnia and Herzegovina (B&H) for reimbursed drugs by Health Insurance Funds (HIF) and out-of-pocket drugs. METHODS: Analysis of reimbursement list and legislation on acces to drugs in B&H is performed. We analysed pricing for reimbursed drugs and out-of-pocket drug prices regulation and explain cost structure.  RESULTS: General drug pricing system is set by Agency for medicines and medical devices of B&H. Prices are defined as maximal wholeseler price (WSP) and pricing is based on referal pricing. Referal countries are Croatia, Serbia, Slovenia, Austria and Italy. B&H price must be set at level of referal price with addoption for patented drug (100%), originator (95%) and generics (90%). Prices are revised each year and published on Agency website. Maximal wholeseler margine is up to 8%, while retail margine is set by entity laws. In Federation maximal retail margine is 25% while in Republic of Srpska margine is fixed on 20% add on WSP. Reimbursable price in Republic of Srpska is defined as lowest offered price for each INN and presentation. Price difference can be paid by patient depenting on preferences. Reimbursed prices for drugs included into Federal reimbursement list is set by nagotiation process with manufacturers. All prices should be revised and adopted annualy to the Agency published prices. Retail margine is not applicable for reimbursed drugs because pharmacy is paid by HIF per prescription according to the agreement. CONCLUSIONS: Even there is intention to unify pharmaceutical market and drug prices in Bosnia and Herzegovine, there are still differences in price and related pricing regulations. Recently published Rule on price control by state Agency should contribute to equalisation of prices in Bosnia and Herzegovina.